Life Science Services

Shipping IMPs for Clinical Trials in Europe: Best Practices

Shipping Investigational Medicinal Products (IMPs) for clinical trials in Europe is a critical yet complex process. IMPs are unapproved drugs used in clinical trials or Early Access Programs (EAPs) for patients with unmet medical needs. Because IMPs are not approved by regulatory agencies like the FDA or EMA, shipping them across borders involves navigating a maze of customs regulations, value-added taxes (VAT), and specific local requirements. In this guide, we outline how biotechs and biopharmas can avoid common mistakes when shipping IMPs to Europe.

The Importance of Key Objectives for Biopharmaceutical Companies
Understand the importance of key objectives for biopharmaceutical companies in Return on pharmaceutical innovation, improving patient engagement, and upskilling digital skills internally are the keys objectives of biopharmaceutical companies.